Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17513444 | 0.90 | ROCK2 (0.70) | ROCK2 | |
| SCHEMBL17538754 | 0.89 | ROCK2 (0.74) | ROCK2 | |
| SCHEMBL17513411 | 0.88 | ROCK2 (0.64) | ROCK2 | |
| SCHEMBL17538753 | 0.88 | ROCK2 (0.74) | ROCK2 | |
| SCHEMBL17513391 | 0.87 | ROCK2 (0.63) | ROCK2 | |
| SCHEMBL17538751 | 0.84 | ROCK2 (0.55) | ROCK2 | |
| SCHEMBL17538761 | 0.84 | ROCK2 (0.59) | ROCK2 | |
| SCHEMBL8542566 | 0.83 | ROCK2 (0.62) | ROCK2 | |
| SCHEMBL17513508 | 0.83 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL17538790 | 0.82 | ROCK2 (0.62) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3183248-B1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3183248-B1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10112939-B2 | Tied-back benzamide derivatives as potent rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| US-20170226105-A1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226105-A1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226105-A1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-10 | — | — | US | disclosed |
| EP-3183248-A1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016028971-A1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-25 | — | — | WO | disclosed |
| WO-2016028971-A1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226105-A1 | TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS | MYLK, ROCK1, MYLK2 | ROCK2 4/4885 |
| US-10112939-B2 | Tied-back benzamide derivatives as potent rock inhibitors | MYLK, ROCK1, MYLK2 | ROCK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.